- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AJMC® in the Press, October 27, 2017
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
An article in the Washington Examiner said that when it comes to health insurance, quality matters too. The article cited a study, “The Effects of Antihypertensive Step-Therapy Protocols on Pharmaceutical and Medical Utilization and Expenditures,” published by The American Journal for Managed Care® (AJMC ®) in 2009. The study found that the initial reductions step therapy causes in pharmaceutical costs are overwhelmed by more than $99 per patient in additional emergency room visits and in-patient hospital stays.
An article on Markets Insider Thursday cited a study published by AJMC®. The study, “A Health Plan's Investigation of Healthy Days and Chronic Conditions,” found that patients with six chronic conditions (coronary artery disease, chronic obstructive pulmonary disease, hypertension, diabetes, congestive heart failure, and depression) experienced a greater number of physically and mentally unhealthy days than the population average.
The National Pharmaceutical Council’s Daily Newsfeed e-mail on Thursday highlighted an article published by AJMC®. The article, “VBID Summit Explores How Congress Can Make High-Deductible Plans Work for Consumers,” reported on the healthcare idea, value-based insurance design (VBID). VBID seeks to remove financial barriers to high-value care. The concept of VBID was pioneered by co-editor-in-chief of AJMC® A. Mark Frederick, MD.
High-Intensity Home-Based Rehabilitation in a Medicare Accountable Care Organization
January 8th 2025High-intensity home-based rehabilitation (HIHR) may substitute for facility-based postacute rehabilitation. Patients in HIHR had better functional outcomes at lower costs than patients in facility-based care.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
Global Trends in Ovarian Cancer Incidence Highlight Regional, Histological Variations
January 7th 2025Between 1988 and 2017, there were significant global variations and trends in ovarian cancer incidence and its subtypes, influenced by genetic, reproductive, and socioeconomic factors.
Read More
Stable Patient Satisfaction Found After Switching From the Humira or Biosimilar CT-P17
January 7th 2025A real-world study in France found patient satisfaction was stable after switching from either the reference product or a low-concentration adalimumab biosimilar to the adalimumab biosimilar CT-P17, a high-concentration, citrate-free formulation.
Read More
